Legacy Solutions LLC Makes New $209,000 Investment in Zoetis Inc. (NYSE:ZTS)

Legacy Solutions LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,282 shares of the company’s stock, valued at approximately $209,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cherry Creek Investment Advisors Inc. raised its stake in shares of Zoetis by 2.0% during the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the last quarter. Hancock Whitney Corp increased its stake in Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after buying an additional 61 shares during the period. Strategy Asset Managers LLC raised its position in Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after buying an additional 62 shares during the last quarter. VeraBank N.A. lifted its stake in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after acquiring an additional 62 shares during the period. Finally, Procyon Advisors LLC boosted its holdings in shares of Zoetis by 1.4% in the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after acquiring an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $156.43 on Wednesday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a market capitalization of $70.05 billion, a P/E ratio of 28.60, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The firm has a 50-day moving average price of $167.70 and a two-hundred day moving average price of $178.44.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, research analysts expect that Zoetis Inc. will post 6.06 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ZTS shares. Piper Sandler cut their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Stifel Nicolaus cut their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $214.90.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.